Perjeta (Pertuzumab) Market Report 2026

Perjeta (Pertuzumab) Market Overview

• The Perjeta (Pertuzumab) market growth in the historic period has been driven by approval of her2 monoclonal antibodies, increasing breast cancer incidence • Market expansion is supported by growth of her2 positive patient identification, expansion into adjuvant therapy settings • Growth Driver: Rising Breast Cancer Incidence Driving Growth Of The Herceptin Biosimilars Market • Market Trend: A Subcutaneous Combination Treatment For HER2-Positive Breast And Colorectal Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Perjeta (Pertuzumab) Market?

Perjeta (pertuzumab) is a targeted therapy used in the treatment of certain types of breast cancer. It is a monoclonal antibody that specifically binds to the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells in HER2-positive breast cancer. The main types of Perjeta (pertuzumab) are human source and animal source. Perjeta (pertuzumab) is a monoclonal antibody developed through recombinant DNA technology and produced using mammalian cell lines, not directly from animal sources. However, the use of animal-derived components may occur in the production process. It includes various products such as monoclonal antibodies and biologic drugs, identified through various indications such as early breast cancer and metastatic breast cancer. It was distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Perjeta (Pertuzumab) Market Growth Forecast?

The perjeta (pertuzumab) market size is expected to see rapid growth in the next few years. It will grow to $2.23 million in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to growth of her2 positive patient identification, expansion into adjuvant therapy settings, increased combination regimen adoption, rising oncology drug spending, global market penetration. Major trends in the forecast period include expansion of her2 targeted combination therapies, growing use in early and metastatic breast cancer, rising adoption of dual her2 blockade, increased focus on precision oncology, improved survival outcomes in her2 positive patients.

Global Perjeta (Pertuzumab) Market Segmentation

1) By Source: Human source, Animal source 2) By Product: Monoclonal Antibody, Biologic Drug 3) By Indication: Early Breast Cancer, Metastatic Breast Cancer 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Is The Driver Of The Perjeta (Pertuzumab) Market?

Rising incidence of breast cancer is expected to propel growth of the Perjeta (pertuzumab) market going forward. Breast cancer refers to a disease where malignant cells develop in breast tissue, often originating in the ducts or lobules. The rising incidence of breast cancer can be attributed to lifestyle changes like increased obesity and sedentary habits, as well as improved early detection through widespread screening programs. Perjeta (pertuzumab) is used to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy to improve treatment outcomes. For instance, in October 2023, according to the Ray of Light Wales, a UK-based not-for-profit charity, the number of people living in the UK after a breast cancer diagnosis is estimated at 600,000 and is projected to double to 1.2 million by 2030. Therefore, the rising incidence of breast cancer is driving the growth of the herceptin biosimilars market.

Key Players In The Global Perjeta (Pertuzumab) Market

Major companies operating in the perjeta (pertuzumab) market are Roche Holding AG

Global Perjeta (Pertuzumab) Market Trends and Insights

The key trend in the Perjeta (pertuzumab) market is focusing on developing technologically advanced solutions, such as subcutaneous combination therapies, to improve patient outcomes and treatment convenience. Subcutaneous combination therapies refer to treatment methods where two or more drugs are combined in a single subcutaneous injection (administered under the skin) to treat a particular condition. For instance, in November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative treatment for subcutaneous administration combines the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing for administration in just 5 to 8 minutes, significantly reducing the time compared to traditional intravenous infusions. Phesgo is indicated for patients with advanced or recurrent HER2-positive colorectal cancer and is the first subcutaneous option for this condition.

What Are Latest Mergers And Acquisitions In The Perjeta (Pertuzumab) Market?

In June 2024, Zydus Pharmaceuticals, an India-based company that offers pharmaceuticals partnered with Dr. Reddy's Laboratories. The partnership between Zydus Lifesciences and Dr. Reddy’s Laboratories aims to enhance access to a pertuzumab biosimilar for HER2-positive breast cancer patients in India, improving affordability, availability, and patient outcomes through combined distribution efforts. Dr. Reddy's Laboratories is an India-based pharmaceutical company that offers pertuzumab biosimilars.

Regional Insights

North America was the largest region in the perjeta (pertuzumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Perjeta (Pertuzumab) Market?

The perjeta (pertuzumab) market consists of sales of products including herceptin, docetaxel, paclitaxel, and carboplatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Perjeta (Pertuzumab) Market Report 2026?

The perjeta (pertuzumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the perjeta (pertuzumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.